Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2

被引:27
作者
De Paola, F
Ridolfi, R
Riccobon, A
Flamini, E
Barzanti, F
Granato, AM
Mordenti, GL
Medri, L
Vitali, P
Amadori, D
机构
[1] Pierantoni Hosp, Dept Med Oncol, I-47100 AUSL Forli, Italy
[2] Ist Oncol Romagnolo, I-47100 Farli, Italy
[3] Pierantoni Hosp, Dept Pathol, I-47100 AUSL Forli, Italy
关键词
TIL; tumour immunosuppression; IL-2;
D O I
10.1038/sj.bjc.6600679
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) epsilon chain, p56(Ick), Fas ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2 and high Bax expression. Notably, they also expressed FasL. After 41 - 48 days of IL-2 culture, TCR 8 chain and p56(Ick) expression of TIL rose to median values of approximately 80 and 30% positive cells, respectively (P<0.001), FasL expression was detected in 45% cells from melanomas (P<0.001) and in 3% from colorectal carcinomas (P = 0.09), and Bax-positive cells increased from 17.5 to 70% (P = 0.005). Moreover, TCR zeta chain-positive cells were significantly increased from baseline (P = 0.001), Bcl-2-positive cells dropped from 50 to 1% (P=0.007) and perforin content was high, while Fas expression was not significantly modified by IL-2 culture, In conclusion, our data suggest that the degree of immunosuppression in TIL from melanomas and colorectal carcinomas is very high, and the apoptosis markers' repertoire of cancer cells resembles that of immune-privileged tissue. Interleukin-2 culture appears to restore lymphocyte activation mechanisms, resulting in consistent FasL expression and perforin production. British Journal of Cancer (2003) 88, 320 - 326. doi: 10. 1038/sj.bjc.6600679 www.bjcancer.com (C) 2003 Cancer Research UK.
引用
收藏
页码:320 / 326
页数:7
相关论文
共 38 条
[1]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[2]   CD43 MONOCLONAL-ANTIBODIES RECOGNIZE THE LARGE SIALOGLYCOPROTEIN OF HUMAN-LEUKOCYTES [J].
BORCHE, L ;
LOZANO, F ;
VILELLA, R ;
VIVES, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (10) :1523-1526
[3]  
Chappell DB, 1999, CANCER RES, V59, P59
[4]   THE DECREASED EXPRESSION OF CD3 XI-CHAINS IN CANCER-PATIENTS IS NOT REVERSED BY IL-2 ADMINISTRATION [J].
FARACE, F ;
ANGEVIN, E ;
VANDERPLANCKE, J ;
ESCUDIER, B ;
TRIEBEL, F .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (06) :752-755
[5]  
FINKE JH, 1993, CANCER RES, V53, P5613
[6]   ADOPTIVE IMMUNOTHERAPY WITH TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA AND RENAL-CELL CARCINOMA - A PILOT-STUDY [J].
GOEDEGEBUURE, PS ;
DOUVILLE, LM ;
LI, H ;
RICHMOND, GC ;
SCHOOF, DD ;
SCAVONE, M ;
EBERLEIN, TJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1939-1949
[7]   Bcl-2 expression in malignant melanoma and its prognostic significance [J].
Grover, R ;
Wilson, GD .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1996, 22 (04) :347-349
[8]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[9]   Prognostic value of biomarkers in malignant melanoma [J].
Hernberg, M ;
Turunen, JP ;
von Boguslawsky, K ;
Muhonen, T ;
Pyrhonen, S .
MELANOMA RESEARCH, 1998, 8 (03) :283-291
[10]  
Lai P, 1996, CLIN CANCER RES, V2, P161